Gastric
Destiny-Gastric 05
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer
Trial overview
Clinical Area
Medical Oncology
Disease
Gastric
Disease site
Gastrointestinal
Study Phase
III
Trial Identifiers
Registration number: NCT06731478
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries